Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Buti

Showing results (671-680 of 1,095) with videos related to

Pageof 110
Sort By:
Frontiers in Oncology|September 2, 2022
Prognostic value of normal sodium levels in patients with metastatic renal cell carcinoma receiving tyrosine kinase inhibitorsGiandomenico Roviello, Martina Catalano, Ugo De Giorgi, et al.
Expert Review of Cardiovascular Therapy|December 13, 2019
Targeted therapy for solid tumors and risk of hypertension: a meta-analysis of 68077 patients from 93 phase III studiesMatteo Santoni, Alessandro Conti, Francesco Massari, et al.
Cancer|July 17, 2015
Impact of long-term tenofovir disoproxil fumarate on incidence of hepatocellular carcinoma in patients with chronic hepatitis BW Ray Kim, Rohit Loomba, Thomas Berg, et al.
Gastroenterology|April 29, 2020
JNJ-56136379, an HBV Capsid Assembly Modulator, Is Well-Tolerated and Has Antiviral Activity in a Phase 1 Study of Patients With Chronic InfectionFabien Zoulim, Oliver Lenz, Joris J Vandenbossche, et al.
Journal of Viral Hepatitis|November 22, 2014
Alisporivir with peginterferon/ribavirin in patients with chronic hepatitis C genotype 1 infection who failed to respond to or relapsed after prior interferon-based therapy: FUNDAMENTAL, a Phase II trialM Buti, R Flisiak, J-H Kao, et al.
Immunity, Inflammation and Disease|November 18, 2014
Optimized fluorescent labeling to identify memory B cells specific for Neisseria meningitidis serogroup B vaccine antigens ex vivoNitya Nair, Ludovico Buti, Elisa Faenzi, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|March 13, 2021
Differential characteristics and outcomes of Asian and non-Asian patients with HBV-related hepatocellular carcinomaDaniel Q Huang, Joseph K Hoang, Jennifer Leong, et al.
Journal of Viral Hepatitis|March 15, 2021
Resistance-associated substitutions after sofosbuvir/velpatasvir/voxilaprevir triple therapy failureDamir Garcia-Cehic, Ariadna Rando, Francisco Rodriguez-Frias, et al.
Journal of Hepatology|April 7, 2009
Baseline characteristics and early on-treatment response predict the outcomes of 2 years of telbivudine treatment of chronic hepatitis BStefan Zeuzem, Edward Gane, Yun-Fan Liaw, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|January 25, 2021
Long-term Patient-Centered Outcomes in Cirrhotic Patients With Chronic Hepatitis C After Achieving Sustained Virologic ResponseZobair M Younossi, Andrei Racila, Andrew Muir, et al.
Pageof 110

Showing results (671-680 of 1,095) with videos related to

Sort By:
Pageof 110
Frontiers in Oncology|September 2, 2022
Prognostic value of normal sodium levels in patients with metastatic renal cell carcinoma receiving tyrosine kinase inhibitorsGiandomenico Roviello, Martina Catalano, Ugo De Giorgi, et al.
Expert Review of Cardiovascular Therapy|December 13, 2019
Targeted therapy for solid tumors and risk of hypertension: a meta-analysis of 68077 patients from 93 phase III studiesMatteo Santoni, Alessandro Conti, Francesco Massari, et al.
Cancer|July 17, 2015
Impact of long-term tenofovir disoproxil fumarate on incidence of hepatocellular carcinoma in patients with chronic hepatitis BW Ray Kim, Rohit Loomba, Thomas Berg, et al.
Gastroenterology|April 29, 2020
JNJ-56136379, an HBV Capsid Assembly Modulator, Is Well-Tolerated and Has Antiviral Activity in a Phase 1 Study of Patients With Chronic InfectionFabien Zoulim, Oliver Lenz, Joris J Vandenbossche, et al.
Journal of Viral Hepatitis|November 22, 2014
Alisporivir with peginterferon/ribavirin in patients with chronic hepatitis C genotype 1 infection who failed to respond to or relapsed after prior interferon-based therapy: FUNDAMENTAL, a Phase II trialM Buti, R Flisiak, J-H Kao, et al.
Immunity, Inflammation and Disease|November 18, 2014
Optimized fluorescent labeling to identify memory B cells specific for Neisseria meningitidis serogroup B vaccine antigens ex vivoNitya Nair, Ludovico Buti, Elisa Faenzi, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|March 13, 2021
Differential characteristics and outcomes of Asian and non-Asian patients with HBV-related hepatocellular carcinomaDaniel Q Huang, Joseph K Hoang, Jennifer Leong, et al.
Journal of Viral Hepatitis|March 15, 2021
Resistance-associated substitutions after sofosbuvir/velpatasvir/voxilaprevir triple therapy failureDamir Garcia-Cehic, Ariadna Rando, Francisco Rodriguez-Frias, et al.
Journal of Hepatology|April 7, 2009
Baseline characteristics and early on-treatment response predict the outcomes of 2 years of telbivudine treatment of chronic hepatitis BStefan Zeuzem, Edward Gane, Yun-Fan Liaw, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|January 25, 2021
Long-term Patient-Centered Outcomes in Cirrhotic Patients With Chronic Hepatitis C After Achieving Sustained Virologic ResponseZobair M Younossi, Andrei Racila, Andrew Muir, et al.
Pageof 110